HIV-1 in Israel, 2010-2018

By the end of 2018 approximately 37.9 million people worldwide were living. Most (25.7 million) reside in Africa, 2.5 million in Europe and only 400,000 in Eastern Mediterranean. Globally, men having sex with men (MSM), injecting drug users (IDU) and sex workers remain the major risk groups of acquiring HIV-1. Although 23.3 million (62%) HIV-1 patients are receiving antiretroviral therapy (ART), drug resistance is still a limitation for the optimal control of HIV-1 infection. In this study we aim to describe HIV-1 infection in Israel between 2010 and 2018.

All patients recorded as HIV-1 positive by the National HIV reference center and diagnosed during the study period will be included. Information on time of diagnosis, sex, age, place of birth and risk group for HIV-1 infection (MSM, IDU, endemic country, heterosexual contacts) will be retrieved from the national data base and analyzed. Transmitted and acquired drug resistance mutations (TDRM and aDRM) will be determined according to the WHO surveillance mutations list (TDRM) or the Stanford HIV resistance database (aDRM), respectively. Logistic regression will be used to assess the association between the different study parameters. Results will be compared to the available HIV-1 data from Europe.